Focusing on next-gen cancer drugs, GSK touts a ‘breakthrough’ at FDA; Aisling raises $280M fund
→ Anyone looking for fresh signs of GlaxoSmithKline’s plans to go much deeper into oncology should check out the pharma giant’s notice that its multiple myeloma drug GSK2857916 just won the FDA’s breakthrough designation. GSK’s Axel Hoos, who’s been running the early-stage oncology effort after the big asset swap with Novartis, said this drug could be a transformational therapy. “Oncology R&D at GSK is focused on developing medicines with transformational potential for patients and we are pleased that our investigational antibody-drug conjugate is the first BCMA targeting agent to receive Breakthrough Therapy and PRIME designation,” he noted. “GSK plans to rapidly advance clinical trials with this promising therapy, alone and in combination with other therapies, to further investigate how GSK2857916 could benefit patients with multiple myeloma.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.